The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.
Douglas Edward Gladstone
Research Funding - MedImmune
Marc Andre
Research Funding - MedImmune
Jan M. Zaucha
Research Funding - MedImmune
Sarit E. Assouline
Research Funding - MedImmune
Naresh Bellam
Research Funding - Facet Biotech; Genentech; Janssen; MedImmune
Nicola Cascavilla
Research Funding - MedImmune
Eric Jourdan
Research Funding - MedImmune; Roche
Amit W. Panwalkar
Research Funding - MedImmune
Caterina Patti
Research Funding - MedImmune
Clemens Schulte
No relevant relationships to disclose
Francesco Zaja
Research Funding - MedImmune
Trishna Goswami
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Nairouz Elgeioushi
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
David Spaner
Research Funding - MedImmune